Browsing Tag
Winrevair
3 posts
Is Merck building the next great cardiometabolic franchise? A closer look at WINREVAIR, enlicitide and Ohtuvayre
See how Merck is building a cardiometabolic growth engine with WINREVAIR, enlicitide and Ohtuvayre—and what it means for investors.
Can Merck sustain its oncology-led momentum? Keytruda, WINREVAIR, and pipeline drive Q3 beat
Merck’s Q3 2025 results beat expectations on Keytruda strength and a rising pipeline. Explore what’s driving EPS upgrades and future growth bets.
Can Merck rebuild its cardiovascular empire post-Keytruda? A closer look at its next decade of drug growth
With Keytruda’s patent expiry nearing, Merck is betting on enlicitide and sotatercept to build a new cardiovascular empire. Can it succeed?